Hyperbaric Oxygen Boosts PD-1 Antibody Delivery and T Cell Infiltration for Augmented Immune Responses Against Solid Tumors.
Xin Liu,Ningbing Ye,Sha Liu,Jiankun Guan,Qingyuan Deng,Zhijie Zhang,Chen Xiao,Zeyang Ding,Bixiang Zhang,Xiaoping Chen,Zifu Li,Xiangliang Yang +11 more
66
TL;DR: In this article, the authors leveraged hyperbaric oxygen (HBO) for the first time to address the two key factors that limit the antitumor efficacy of T cell immune checkpoint blockade inhibitors, e.g., programmed cell death-1 antibody (PD-1 Ab), against solid tumors.
read more
Abstract: Aberrant mechanical properties and immunosuppression are the two key factors that limit the antitumor efficacy of T cell immune checkpoint blockade inhibitors, e.g., programmed cell death-1 antibody (PD-1 Ab), against solid tumors in the clinic. This study leverages hyperbaric oxygen (HBO) for the first time to address these two issues and reports the PD-1-Ab-mediated immune responses against various stroma-rich solid malignancies. The results demonstrate that HBO promoted PD-1 Ab delivery and T cells infiltration into tumor parenchyma by depleting the extracellular matrix's main components, such as collagen and fibronectin. Furthermore, HBO disrupts hypoxia-mediated immunosuppression and helps PD-1 Ab trigger robust cytotoxic T lymphocytes and long-lasting immunological memory to inhibit tumor relapses. Such enhanced immune responses are effective in solid tumors from rodents and the cancer cells from hepatocellular carcinoma patients. The results illustrate that HBO bolsters antitumor efficacy of PD-1 Ab, and the HBO-PD-1 Ab combination is a promising stroma-rich solid tumors' treatment in the clinic.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
TL;DR: In this paper , the authors investigated the potential factors in the development of hypoxia in cancer, changes in signaling pathways that occur in cancer cells to adapt to hypoxic environments, the mechanisms of hypoxide-induced cancer immune tolerance, chemotherapeutic tolerance, and enhanced radiation tolerance, as well as the insights and applications of hypoxygenation in cancer therapy.
Hydroxyethyl starch-folic acid conjugates stabilized theranostic nanoparticles for cancer therapy.
Chong Wang,Qiang Wang,Huimin Wang,Zheng Li,Jitang Chen,Zhijie Zhang,Haowen Zeng,Ximiao Yu,Xiaoquan Yang,Xiang Yang,Zifu Li +10 more
TL;DR: In this paper , the authors employed carbamate disulfide bridged doxorubicin dimeric prodrug as pharmaceutical ingredient, marketed IR780 iodide as photothermal agent, and biocompatible hydroxyethyl starch-folic acid conjugates as amphiphilic surfactant to prepare a theranostic nanomedicine (FDINs), which could actively target at TNBC 4T1 tumor tissues and achieve reduction-responsive drug release with high glutathione concentration in cancer cells and CSCs.
47
Hypoxia signaling in cancer: Implications for therapeutic interventions
TL;DR: In this paper , the authors discuss the critical role of hypoxia in tumor development, including tumor metabolism, tumor immunity, and tumor angiogenesis, and discuss the prospects of hyperoxia therapy in cancer treatment.
45
Rational Design of Nanotherapeutics Based on the Five Features Principle for Potent Elimination of Cancer Stem Cells.
TL;DR: The studies suggest that intractable CSCs can be tackled with a material-based approach, highlight the critical role of the five features principle in designing effective nanotherapeutics, and pinpoint the significance of drug delivery efficiency in eliminating CSC's and bulk cancer cells.
45
Innovative strategies for photodynamic therapy against hypoxic tumor
Xiaotong Li,Lei Chen,Miaoting Huang,Shaoting Zeng,Jiayi Zheng,Shuyin Peng,Yuqing Wang,Hong Bo Cheng,Shi-Ying Li +8 more
TL;DR: Wang et al. as discussed by the authors summarized the latest progresses in the development of innovative strategies to improve photodynamic therapy efficacy against hypoxic tumor, which were classified into O2dependent PDT, O2-independent PDT and synergistic therapy.
43
References
Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy
Priyamvada Jayaprakash,Midan Ai,Arthur Liu,Arthur Liu,Pratha Budhani,Todd Bartkowiak,Todd Bartkowiak,Jie Sheng,Casey R. Ager,Casey R. Ager,Courtney Nicholas,Ashvin R. Jaiswal,Yanqiu Sun,Krishna Shah,Sadhana Balasubramanyam,Nan Li,Guocan Wang,Jing Ning,Anna Zal,Tomasz Zal,Tomasz Zal,Michael A. Curran,Michael A. Curran +22 more
TL;DR: Hypoxia disruption and T cell checkpoint blockade may sensitize some of the most therapeutically resistant cancers to immunotherapy.
Bioinspired Hybrid Protein Oxygen Nanocarrier Amplified Photodynamic Therapy for Eliciting Anti-tumor Immunity and Abscopal Effect
Chen Zhikuan,Lanlan Liu,Ruijing Liang,Zhenyu Luo,Huamei He,Zhihao Wu,Hao Tian,Mingbin Zheng,Yifan Ma,Lintao Cai +9 more
TL;DR: Oxygen-augmented immunogenic PDT of C@HPOC could destroy primary tumors and effectively suppress distant tumors and lung metastasis in a metastatic triple-negative breast cancer model by evoking systemic anti-tumor immunity.
330
Oxidative stress is fundamental to hyperbaric oxygen therapy.
TL;DR: Reactive species are now recognized to play a major role in cell signal transduction cascades, and the discussion will focus on how hyperbaric oxygen acts through these pathways to mediate wound healing and ameliorate postischemic and inflammatory injuries.
297
Mechanisms and impact of altered tumour mechanics.
Hamid Mohammadi,Erik Sahai +1 more
TL;DR: In this Review, Mohammadi and Sahai discuss recent insights into how altered tumour mechanics arise and how this affects tumorigenesis.
261
Engineering nanoparticles to locally activate T cells in the tumor microenvironment
Dangge Wang,Tingting Wang,Haijun Yu,Bing Feng,Lei Zhou,Fangyuan Zhou,Bo Hou,Hanwu Zhang,Min Luo,Yaping Li,Yaping Li +10 more
TL;DR: The development of tumor microenvironment–activatable anti-PDL1 antibody nanoparticles for combination immunotherapy designed to overcome immunological tolerance of tumors is reported.
233